Compare Cytokinetics Inc (CYTK) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Cytokinetics Inc trades at $81.96 (market cap $11.12B), while iShares 10 20 Year Treasury Bond ETF trades at $98.14. The key difference: Cytokinetics Inc is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | TLH | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | Fixed Income |
52-Week High | $87.26 | $105.36 |
52-Week Low | $33.23 | $97.13 |
Enterprise Value | $11.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
TLH stock trades at $97.98, down 0.53% today, with a bearish technical signal from moving averages but bullish oscillators. The company has announced dividends for H1-26 and H2-26, yet key financial ratios are unavailable. Recent news highlights broader market volatility from Fed policy uncertainty and geopolitical tensions.
The outlook is cautious due to missing fundamental data and bearish technicals. Risks include macroeconomic headwinds and lack of visibility on earnings. Investment opportunity hinges on future financial disclosures and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
